SCHEMBL1634720

SCHEMBL1634720

CC(C)NC(=O)c1ccc(Nc2ncc3c(Cl)ccc(OC4CCNCC4)c3n2)cc1F

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PTK2 Q05397 10/20 0.47
JAK2 O60674 4/20 0.43
JAK1 P23458 3/20 0.43
JAK3 P52333 3/20 0.43
TYK2 P29597 1/20 0.43
TBK1 Q9UHD2 1/20 0.42
BRD4 O60885 5/20 0.41
CDK1 P06493 2/20 0.41
CDK4 P11802 2/20 0.41
CCNB1 P14635 2/20 0.41
CCND1 P24385 2/20 0.41
CCNE1 P24864 2/20 0.41
CDK2 P24941 2/20 0.41
SCN9A Q15858 1/20 0.40
BRDT Q58F21 2/20 0.40
BRD2 P25440 1/20 0.40
BRD3 Q15059 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13498302 0.90 PTK2 (0.50) PTK2JAK2JAK1JAK3TYK2
SCHEMBL1632909 0.87 TBK1 (0.53) PTK2JAK2JAK1JAK3TYK2
SCHEMBL1632728 0.86 JAK2 (0.59) PTK2JAK2JAK1JAK3TYK2
SCHEMBL1634969 0.83 JAK2 (0.44) PTK2JAK2JAK1JAK3TYK2
SCHEMBL1632647 0.83 LRRK2 (0.44) PTK2JAK2JAK1JAK3BRD4
SCHEMBL1634346 0.82 JAK2 (0.57) PTK2JAK2JAK1JAK3TYK2
SCHEMBL1633506 0.80 JAK2 (0.57) PTK2JAK2JAK1JAK3TYK2
SCHEMBL1634153 0.79 JAK2 (0.47) PTK2JAK2JAK1JAK3TYK2
SCHEMBL1634717 0.79 JAK2 (0.50) JAK2JAK1JAK3TYK2SCN9A
SCHEMBL1633174 0.79 JAK2 (0.45) JAK2JAK1JAK3TYK2TBK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7932262-B2 Quinazolines for PDK1 inhibition NOVARTIS AG (CH) 2011-04-26 US disclosed
US-7932262-B2 Quinazolines for PDK1 inhibition NOVARTIS AG (CH) 2011-04-26 US disclosed
US-7932262-B2 Quinazolines for PDK1 inhibition NOVARTIS AG (CH) 2011-04-26 US disclosed